CDK9-IN-2
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI (8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma (MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.
Product Specifications
CAS Number
[1263369-28-3]
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk9-in-2.html
Purity
98.72
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
ClC1=CN=C(N[C@@H]2CC[C@@H](N)CC2)C=C1C3=NC(NCC4=CC(F)=CC=C4)=CC=C3
Molecular Formula
C23H25ClFN5
Molecular Weight
425.93
References & Citations
[1]Michel Faure, et al. Pharmacodynamic markers associated with cyclin-dependent kinase inhibitors. From PCT Int. Appl. (2012), WO 2012131594A1
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK9
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
